This product is a human monoclonal antibody specific to ZIKV NS1. This antibody can be used in a variety of applications, such as ELISA, WB, Neut.
Figure 1 ELISAs were performed against MR766 ZIKV supernatant to assess binding activities.
ELISAs were performed as duplicates, and results are reported as values of the area under the concentration-time curve (AUC). Error bars represent standard errors of the means (SEM).
Bailey, M. J., Broecker, F., Freyn, A. W., Choi, A., Brown, J. A., Fedorova, N., ... & Tan, G. S. (2019). Human monoclonal antibodies potently neutralize Zika virus and select for escape mutations on the lateral ridge of the envelope protein. Journal of virology, 93(14), e00405-19.
Figure 2 ELISAs were performed against recombinant MR766 envelope protein to assess binding activities.
ELISAs were performed as duplicates, and results are reported as values of the area under the concentration-time curve (AUC). Error bars represent standard errors of the means (SEM).
Bailey, M. J., Broecker, F., Freyn, A. W., Choi, A., Brown, J. A., Fedorova, N., ... & Tan, G. S. (2019). Human monoclonal antibodies potently neutralize Zika virus and select for escape mutations on the lateral ridge of the envelope protein. Journal of virology, 93(14), e00405-19.
Figure 3 ELISAs were performed against recombinant MR766 NS1 protein to assess binding activities.
ELISAs were performed as duplicates, and results are reported as values of the area under the concentration-time curve (AUC). Error bars represent standard errors of the means (SEM).
Bailey, M. J., Broecker, F., Freyn, A. W., Choi, A., Brown, J. A., Fedorova, N., ... & Tan, G. S. (2019). Human monoclonal antibodies potently neutralize Zika virus and select for escape mutations on the lateral ridge of the envelope protein. Journal of virology, 93(14), e00405-19.
Figure 4 Neutralization activity of 12 antibodies against MR766 ZIKV.
Nonneutralizing antibody AA12 is designated n.n.
Bailey, M. J., Broecker, F., Freyn, A. W., Choi, A., Brown, J. A., Fedorova, N., ... & Tan, G. S. (2019). Human monoclonal antibodies potently neutralize Zika virus and select for escape mutations on the lateral ridge of the envelope protein. Journal of virology, 93(14), e00405-19.
Figure 5 Neutralization activity shown as IC50 values.
Bailey, M. J., Broecker, F., Freyn, A. W., Choi, A., Brown, J. A., Fedorova, N., ... & Tan, G. S. (2019). Human monoclonal antibodies potently neutralize Zika virus and select for escape mutations on the lateral ridge of the envelope protein. Journal of virology, 93(14), e00405-19.
Figure 6 Vero cells were infected with MR766 ZIKV and used as targets for measuring Fc-FcγR effector functions with a genetically modified Jurkat cell line expressing human FcγRIIIa with an inducible luciferase reporter gene.
Fold induction was measured in relative light units, and results were compared to infected cells with no antibody added. Error bars represent standard error of the means (SEM).
Bailey, M. J., Broecker, F., Freyn, A. W., Choi, A., Brown, J. A., Fedorova, N., ... & Tan, G. S. (2019). Human monoclonal antibodies potently neutralize Zika virus and select for escape mutations on the lateral ridge of the envelope protein. Journal of virology, 93(14), e00405-19.
Figure 7 To examine whether enhancement of flavivirus infection in vitro is observed, monoclonal antibodies were incubated with ZIKV and added to FcγR-bearing K562 cells.
All monoclonal antibodies were tested at a starting concentration of 3.3 μg per ml and serially diluted 4-fold. Both assays were run in duplicate, and fold induction was measured as the percentage of infected cells as determined by flow cytometry divided by the percentage of infected cells with no antibody added (virus alone).
Bailey, M. J., Broecker, F., Freyn, A. W., Choi, A., Brown, J. A., Fedorova, N., ... & Tan, G. S. (2019). Human monoclonal antibodies potently neutralize Zika virus and select for escape mutations on the lateral ridge of the envelope protein. Journal of virology, 93(14), e00405-19.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-AP485-YC-S(P) | Recombinant Human Anti-ZIKV NS1 Antibody scFv Fragment (HPAB-AP485-YC-S(P)) | ELISA, FC, IF, ADCC Assay, FuncS | Human scFv |
HPAB-AP486-YC-S(P) | Recombinant Human Anti-ZIKV NS1 Antibody scFv Fragment (HPAB-AP486-YC-S(P)) | ELISA, FC, IF, ADCC Assay | Human scFv |
HPAB-AP487-YC-S(P) | Recombinant Human Anti-ZIKV NS1 Antibody scFv Fragment (HPAB-AP487-YC-S(P)) | ELISA, FC, IF, ADCC Assay | Human scFv |
HPAB-AP488-YC-S(P) | Recombinant Human Anti-ZIKV NS1 Antibody scFv Fragment (HPAB-AP488-YC-S(P)) | ELISA, FC, IF, ADCC Assay | Human scFv |
There are currently no Customer reviews or questions for FAMAB-0755WJ. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.